Tuesday, November, 12, 2019 01:32:17

TLC and 3SBio partner to commercialize two NanoX products in China

A clinical-stage specialty pharmaceutical company Taiwan Liposome Company Ltd. and 3SBio Inc, China’s leading biopharmaceutical company have reportedly  entered into an exclusive partnership intended to commercialize two liposomal products in China, using TLC’s proprietary NanoX technology platform. As per the alliance, TLC and 3SBio will …

U.S. FDA grants Fast Track designation for Iovance’s LN-145 therapy

With the Fast Track designation, Iovance is likely to increase the frequency of its communication with the U.S. FDA. Reputed biotechnology company Iovance Biotherapeutics, Inc., has reportedly been granted the Fast Track designation for its adoptive cell therapy LN-145, developed using its proprietary TIL manufacturing …

AusCann signs deal with MediPharm Labs to purchase cannabis resin

The latest move underlines MediPharm’s first international export deal. AusCann Group Holdings Ltd. (AC8), an Australian cannabis medicine company, has reportedly entered into a supply agreement with the leading cannabis extractor in Canada, MediPharm Labs Corp., for the purchase of cannabis resin. AusCann, for the …

Reata announces positive results from bardoxolone phase 2 study

The study specifies the possibility of preventing or delaying kidney failure and the need for dialysis or a kidney transplant in patients with rare chronic kidney disease. U.S. clinical-stage biopharmaceutical firm, Reata Pharmaceuticals, Inc. has recently announced its final, positive result from the focal segmental …